Abiopharma

🔍 O'Keefe Kylie (Executive)

Company: uniQure N.V. (QURE)

Report Date: 2026-03-04

Detailed Transactions and Holdings:

• Acquired 19,800 shares of Ordinary Shares (Direct)
  Date: 2026-03-04 | Code: A | equity_swap_involved: 0 | shares_owned_after: 124,800.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 31,900 shares of Stock Option (Right to Buy) at $9.04 per share (Derivative)
  Date: 2026-03-04 | Code: A | Expires: 2036-03-04 | equity_swap_involved: 0 | shares_owned_after: 31,900.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates.
• F2: The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates.